SEC Company Response from Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704) (CLRB) — Nov 14, 2016

Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)
Date: Nov. 14, 2016 · CIK: 0001279704 · Accession: 0001144204-16-133496

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-214310

Date

November 14, 2016

Author

/s/Paul Bork

Form

CORRESP

Company

Cellectar Biosciences, Inc. (CLRB) (CIK 0001279704)

Letter

Seaport West

155 Seaport Boulevard

Boston, MA 02210-2600

617 832 1000 main

617 832 7000 fax

November 14, 2016

VIA EDGAR

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

Re: Cellectar Biosciences, Inc. (CIK 0001279704)

Registration Statement on Form S-1

Filed October 28, 2016

File No. 333-214310

Ladies and Gentlemen:

This letter constitutes supplemental correspondence on behalf of Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), related to the above-referenced filing (the “Registration Statement”), and is filed together with Amendment No. 1 to the Registration Statement (“Amendment No. 1”).

Please direct any communications concerning Amendment No. 1 to the undersigned at (617) 832-1113, email—pbork@foleyhoag.com, or, in my absence, Gabrielle Bernstein at (617) 832-1161, email—gbernstein@foleyhoag.com. The email address of the Company’s agent for service is jcaruso@cellectar.com.

Very truly yours,
/s/Paul Bork

Show Raw Text

CORRESP
1
filename1.htm

    Seaport
                           West

                           155 Seaport Boulevard

                           Boston, MA 02210-2600

617 832 1000 main

617 832 7000 fax

November 14, 2016

VIA EDGAR

Securities and Exchange Commission

Division of Corporate Finance

100 F Street, N.E.

Washington, DC 20549

 Re: Cellectar Biosciences, Inc. (CIK 0001279704)

Registration Statement on Form S-1

Filed October 28, 2016

File No. 333-214310

Ladies and Gentlemen:

This letter constitutes supplemental correspondence
on behalf of Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), related to the above-referenced filing
(the “Registration Statement”), and is filed together with Amendment No. 1 to the Registration Statement (“Amendment
No. 1”).

Please direct any communications concerning
Amendment No. 1 to the undersigned at (617) 832-1113, email—pbork@foleyhoag.com, or, in my absence, Gabrielle Bernstein
at (617) 832-1161, email—gbernstein@foleyhoag.com. The email address of the Company’s agent for service is jcaruso@cellectar.com.

    Very truly yours,

    /s/Paul Bork

    Paul Bork

 cc: G. Bernstein, Esq.

    ATTORNEYS AT LAW
    BOSTON   |   NEW
    YORK   |   PARIS   |   WASHINGTON   |   FOLEYHOAG.COM

SecProbe.io